--- title: "Apimeds Pharmaceuticals sets reverse split date of July 24" url: "https://aibio.space/news/apimeds-pharmaceuticals-sets-reverse-split-date-july-24/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-07-13" section: "Listings" tickers: "AMEX:APUS" source: "https://www.sec.gov/Archives/edgar/data/1894525/000121390026077591/ea0297843-8k_apimeds.htm" summary: "The company said on July 13, 2026 that its one-for-ten reverse split would take effect on July 24, after a March 2026 target passed without a filing." --- By the aibio.space news desk. Sources - [Apimeds Pharmaceuticals US, Inc. 8-K (2026-07-13)](https://www.sec.gov/Archives/edgar/data/1894525/000121390026077591/ea0297843-8k_apimeds.htm) - [Apimeds Pharmaceuticals US, Inc. 10-K (2026-05-04): business](https://www.sec.gov/Archives/edgar/data/1894525/000121390026051139/ea0288344-10k_apimeds.htm) - [Apimeds Pharmaceuticals US, Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1894525/000121390026051139/) [APUS](https://aibio.space/companies/apimeds-pharmaceuticals-us/) 2026-07-13 # Apimeds Pharmaceuticals sets reverse split date of July 24 Tickers [APUS](https://aibio.space/companies/apimeds-pharmaceuticals-us/) The company said on July 13, 2026 that its one-for-ten reverse split would take effect on July 24, after a March 2026 target passed without a filing. ## Key facts - **Company**: Apimeds Pharmaceuticals US, Inc. (AMEX: APUS) - **News type**: Listings - **Primary source**: [Apimeds Pharmaceuticals US, Inc. 8-K (2026-07-13)](https://www.sec.gov/Archives/edgar/data/1894525/000121390026077591/ea0297843-8k_apimeds.htm) *The Capitol in autumn. CC0, via rawpixel. The picture shows the field, not the companies named.* Apimeds Pharmaceuticals US, Inc. said in a [Form 8-K](https://www.sec.gov/Archives/edgar/data/1894525/000121390026077591/ea0297843-8k_apimeds.htm) dated July 13, 2026 that it expected to file a charter amendment with the Delaware Secretary of State on or about July 23, 2026. The reverse stock split would then become effective as of 12:01 a.m. Eastern Time on July 24, 2026, and the common stock was expected to begin trading on a split-adjusted basis on NYSE American LLC under the symbol APUS at the open of trading that day. Dr. Vin Menon, Chief Executive Officer, signed the report. ## Why the date moved On December 1, 2025, stockholders holding a majority of the voting power approved a one-for-ten reverse split and a corresponding charter amendment by written consent. The company filed and mailed an information statement under Rule 14c-2, dated February 26, 2026 and first mailed to stockholders on March 5, 2026. The split could not take effect until at least 20 calendar days after that mailing. The company had previously announced that it expected to file the charter amendment on or about March 25, 2026, with the split becoming effective March 26, 2026. It did not file the charter amendment on that date. The company said the waiting period has now passed. ## The terms Once effective, every ten shares of issued and outstanding common stock will automatically be combined into one share. The new CUSIP number will be 03771D201. The filing refers readers to the reverse stock split section of the information statement for further detail. The company said it would announce the effectiveness of the split in a later Current Report on Form 8-K. On December 1, 2025, the company entered into and closed an Agreement and Plan of Merger with Apimeds Merger Sub, Inc., MindWave Innovations Inc., Lokahi Therapeutics, Inc. and Erik Emerson, who acted as representative for the Bio Business. Merger Sub merged into MindWave, which survived as a direct wholly owned subsidiary of the company. The annual report says the holders of MindWave common stock were to receive preferred stock and a common stock allocation capped at 0% of the common shares outstanding under the merger agreement, structured so that they would hold, on an as-converted and fully diluted basis, 90.9% of the company's equity capital as of the closing. Stockholders holding approximately 51% of the common stock approved by written consent on December 1, 2025 the conversion of the Series A Convertible Preferred Stock, the conversion of convertible notes issued under a securities purchase agreement with institutional investors, a 1-for-10 reverse split with a change in par value from $0.01 to $0.001, an increase in the 2024 Equity Incentive Plan to 2,096,679 shares, and the 2025 Equity Incentive Plan. The annual report says the company filed and mailed an information statement under Rule 14c-2 and that these actions would not take effect until at least 20 calendar days after mailing. The annual report said the merger and related conversions would cause a change in control, so the company would have to submit a new listing application to NYSE American. For the fiscal year ended December 31, 2025, the company reported research and development expense of $1.6 million and a net loss of $6.0 million, compared with a net loss of $1.4 million for 2024. Cash from operations was negative $8.9 million in 2025 and negative $733,526 in 2024. ## What the split does not fix A reverse split changes the share count, not the business. The 8-K gives no reason for the delay after the March 25 target, and it says nothing about the company's cash. The net loss was $6.0 million in 2025, and cash from operations was negative $8.9 million against negative $733,526 the year before. The conversions of preferred stock and notes that stockholders approved would sit on top of the split. Under the merger terms, MindWave holders would hold 90.9% of the equity on an as-converted basis, so existing holders face heavy dilution once those conversions take place. The company has said it will announce the split's effectiveness in a later 8-K, and it will not carry out the conversions until NYSE American approves its new listing application. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story APUS Apimeds Pharmaceuticals US, Inc. AMEX ยท United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/apimeds-pharmaceuticals-sets-reverse-split-date-july-24/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Apimeds Pharmaceuticals sets reverse split date of July 24", 2026-07-13, https://aibio.space/news/apimeds-pharmaceuticals-sets-reverse-split-date-july-24/